Novartis' Sandoz will discontinue operations at its Maharashtra, India site by December 2016, as part of global plans to optimize manufacturing.
The site, located in west-central India, employs 170 people and manufactures antibiotics and APIs.
Sandoz will continue to serve the India market, but will instead focus its manufacturing at its two other, larger sites in India.
Read the Hindu Business Line release